News

The University of Kentucky Spinal Cord and Brain Injury Research Center (SCoBIRC) hosted a symposium last week featuring its first class of African American Research Training Scholars (AARTS).

The Human Development Institute (HDI) will be leading an effort to improve capacity of health care to serve children with neurodevelopmental disabilities and their families throughout Kentucky.

The Research Priority Area supports a "collaborative matrix," bringing together diverse groups of investigators, trainees and research groups from nine different colleges across the university campus.

The grant will allow coordination and expansion of existing efforts to improve stroke-related health outcomes.

UK Neuroscience Professor Greg Gerhardt's new research program will provide answers to questions about the role of neurotransmitters in the progression of Alzheimer’s disease.

The discovery could yield a key insight which could have broad implications for understanding neurological changes associated with aging.

Goldstein also is co-director of the Kentucky Neuroscience Institute, co-director of the UK Neuroscience Research Priority Area and interim director of the UK-Norton Healthcare Stroke Care Network. Goldstein’s two-year term on the board of directors begins later this month.

Hyperbaric oxygen treatment (HBO) is a treatment that is now being experimentally studied in adult patients with severe traumatic brain injuries (TBI). Hyperbaric oxygen treatment is a specialized way, using a pressure chamber, to dramatically increase the amount of oxygen delivered to body tissues.

Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.

A $2.9 million grant from the NIH is supporting a multidisciplinary team of UK researchers in continuing their work to find therapeutic strategies to resolve neurovascular inflammation and repair blood-brain barrier dysfunction in epilepsy.